BRPI0917565A2 - derivados de pirazolo [5,1-b] oxazol como antagonistas de crf1 - Google Patents

derivados de pirazolo [5,1-b] oxazol como antagonistas de crf1

Info

Publication number: BRPI0917565A2
Authority: BR; Brazil
Prior art keywords: pyrazolo; oxazole derivatives; crf1 antagonists; crf1; antagonists
Prior art date: 2008-08-06

Application number

BRPI0917565A

Other languages

English (en)

Inventor

Andrew James Culshaw

François Gessier

Helen Elizabeth Oakman

Ian Bruce

James Neef

Jeffrey Mckenna

Nicholas James Devereux

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-06

Filing date

2009-08-04

Publication date

2015-11-17

2009-08-04 Application filed by Novartis Ag filed Critical Novartis Ag

2015-11-17 Publication of BRPI0917565A2 publication Critical patent/BRPI0917565A2/pt

Links

101150105710 CRF1 gene Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
BKRKYGDGROPRDS-UHFFFAOYSA-N pyrazolo[5,1-b][1,3]oxazole Chemical class O1C=CN2N=CC=C21 BKRKYGDGROPRDS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Addiction (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)

BRPI0917565A 2008-08-06 2009-08-04 derivados de pirazolo [5,1-b] oxazol como antagonistas de crf1 BRPI0917565A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP08161930		2008-08-06
US20509609P	2009-01-14	2009-01-14
EP09150553		2009-01-14
PCT/EP2009/060094 WO2010015628A1 (en)	2008-08-06	2009-08-04	Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists

Publications (1)

Publication Number	Publication Date
BRPI0917565A2 true BRPI0917565A2 (pt)	2015-11-17

Family

ID=41653505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0917565A BRPI0917565A2 (pt)	2008-08-06	2009-08-04	derivados de pirazolo [5,1-b] oxazol como antagonistas de crf1

Country Status (18)

Country	Link
US (1)	US7994203B2 (pt)
EP (1)	EP2328902A1 (pt)
JP (1)	JP2011529943A (pt)
KR (1)	KR20110051226A (pt)
CN (1)	CN102171220A (pt)
AR (1)	AR073262A1 (pt)
AU (1)	AU2009279137A1 (pt)
BR (1)	BRPI0917565A2 (pt)
CA (1)	CA2733176A1 (pt)
CO (1)	CO6351723A2 (pt)
EA (1)	EA201100303A1 (pt)
EC (1)	ECSP11010801A (pt)
IL (1)	IL211030A0 (pt)
MA (1)	MA32537B1 (pt)
MX (1)	MX2011001392A (pt)
TW (1)	TW201011039A (pt)
UY (1)	UY32029A (pt)
WO (1)	WO2010015628A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2266990T1 (sl)	2008-04-15	2013-01-31	Eisai R&D Management Co. Ltd.	Spojina 3-fenilpirazolo(5,1-b)tiazola
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
JPWO2011043387A1 (ja)	2009-10-08	2013-03-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピラゾロオキサゾール化合物
AR080055A1 (es) *	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR086554A1 (es)	2011-05-27	2014-01-08	Novartis Ag	Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015525202A (ja)	2012-05-03	2015-09-03	ノバルティスアーゲー	グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
JP6585625B2 (ja)	2014-01-21	2019-10-02	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
EP3661500B1 (en)	2017-07-31	2026-01-07	Novartis AG	Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MA54395A (fr)	2018-12-07	2022-03-16	Neurocrine Biosciences Inc	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
CN114502162B (zh)	2019-09-27	2025-03-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5426296A (en) *	1995-04-04	1996-10-23	E.I. Du Pont De Nemours And Company	Herbicidal heteroaryl-substituted anilides
KR20040034594A (ko) *	2001-01-26	2004-04-28	브리스톨-마이어스스퀴브컴파니	코르티코트로핀 방출 인자 억제제로서의 이미다졸릴 유도체

2009
- 2009-08-03 US US12/462,417 patent/US7994203B2/en not_active Expired - Fee Related
- 2009-08-04 EP EP09804561A patent/EP2328902A1/en not_active Withdrawn
- 2009-08-04 CN CN2009801394474A patent/CN102171220A/zh active Pending
- 2009-08-04 KR KR1020117005158A patent/KR20110051226A/ko not_active Withdrawn
- 2009-08-04 MX MX2011001392A patent/MX2011001392A/es not_active Application Discontinuation
- 2009-08-04 WO PCT/EP2009/060094 patent/WO2010015628A1/en not_active Ceased
- 2009-08-04 JP JP2011521562A patent/JP2011529943A/ja not_active Withdrawn
- 2009-08-04 EA EA201100303A patent/EA201100303A1/ru unknown
- 2009-08-04 AU AU2009279137A patent/AU2009279137A1/en not_active Abandoned
- 2009-08-04 BR BRPI0917565A patent/BRPI0917565A2/pt not_active Application Discontinuation
- 2009-08-04 CA CA2733176A patent/CA2733176A1/en not_active Abandoned
- 2009-08-04 AR ARP090102986A patent/AR073262A1/es unknown
- 2009-08-04 UY UY0001032029A patent/UY32029A/es not_active Application Discontinuation
- 2009-08-05 TW TW098126427A patent/TW201011039A/zh unknown
2011
- 2011-02-01 CO CO11011419A patent/CO6351723A2/es not_active Application Discontinuation
- 2011-02-02 EC EC2011010801A patent/ECSP11010801A/es unknown
- 2011-02-03 IL IL211030A patent/IL211030A0/en unknown
- 2011-02-03 MA MA33581A patent/MA32537B1/fr unknown

Also Published As

Publication number	Publication date
JP2011529943A (ja)	2011-12-15
IL211030A0 (en)	2011-04-28
WO2010015628A1 (en)	2010-02-11
US20100035874A1 (en)	2010-02-11
EP2328902A1 (en)	2011-06-08
AU2009279137A8 (en)	2011-03-03
AR073262A1 (es)	2010-10-28
AU2009279137A1 (en)	2010-02-11
MA32537B1 (fr)	2011-08-01
MX2011001392A (es)	2011-03-25
CO6351723A2 (es)	2011-12-20
US7994203B2 (en)	2011-08-09
EA201100303A1 (ru)	2011-10-31
TW201011039A (en)	2010-03-16
CN102171220A (zh)	2011-08-31
CA2733176A1 (en)	2010-02-11
ECSP11010801A (es)	2011-03-31
UY32029A (es)	2010-03-26
KR20110051226A (ko)	2011-05-17

Legal Events

Date	Code	Title	Description
2016-04-12	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2016-07-26	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]

Publication	Publication Date	Title
BR112013015430A2 (pt)	2016-09-20	derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
IL211030A0 (en)	2011-04-28	Pyrazolo [5,1-b] oxazole derivatives as crf1 antagonists
BRPI0810462A2 (pt)	2014-10-14	Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0717023A2 (pt)	2014-03-11	Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0815135A2 (pt)	2015-02-03	Derivados de azepina como inibidores de gama secretase.
BRPI0813768A2 (pt)	2014-12-30	Derivados de benzazepina úteis como antagonistas de vasopressina
BRPI0718266A2 (pt)	2014-01-07	Compostos heterocíclicos como agentes anti-inflamatórios.
BRPI0906625A2 (pt)	2015-07-14	Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0919738A2 (pt)	2015-12-08	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios
EP2210880A4 (en)	2012-03-07	benzoxazinone-
BR112012003704A2 (pt)	2016-04-05	derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BRPI0817061A2 (pt)	2015-03-24	Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0717937A2 (pt)	2013-12-03	Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0815948A2 (pt)	2019-09-24	"compostos heterocíclicos como antagonistas de receptorncrth2"
CU23828B1 (es)	2012-06-29	Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
BRPI0812825A2 (pt)	2014-12-09	Derivados ftalazinona como inibidores de parp-1
BRPI0817562A2 (pt)	2017-05-02	derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BR112013022917A2 (pt)	2016-12-06	derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace)
CR10849A (es)	2009-08-12	Derivados de benzamida como agonistas del receptor ep4
BRPI0909157A2 (pt)	2015-11-24	compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0920895A2 (pt)	2015-12-22	compostos antibióticos de oxazolidinona tricíclica
BRPI0823082A2 (pt)	2015-06-16	Uso derivados de sesquiterpeno
BRPI0915991A2 (pt)	2019-09-24	derivados de sulfamida substituída
BRPI0914301A2 (pt)	2015-10-13	derivados de pirimidin-4-ona substituída
BRPI0718494A2 (pt)	2014-01-21	Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina